Independent regulation of prostaglandins and monocyte chemoattractant protein-1 by interleukin-1beta and hCG in human endometrial cells.
BACKGROUND
Inflammatory mediators such as prostaglandins (PG), chemokines, cytokines and their interactions regulate reproductive functions. The relationship between PG and monocyte chemoattractant protein-1 (MCP-1) has not been elucidated in human endometrium. The presence of hCG receptors in the human endometrium suggests that this embryonic signal may exert a local function in this tissue. Our objectives were to investigate the possible association between PG and MCP-1 and to examine the role of hCG in interleukin-1beta (IL-1beta)-regulated PG and MCP-1 production in human endometrium.


METHODS
Primary cell cultures isolated from endometrial biopsies were used as an in vitro model. PG and MCP-1 levels were measured in the culture medium.


RESULTS
IL-1beta stimulates the production of both PG and MCP-1. Neither COX inhibitors nor direct addition of PG affects MCP-1 production. By contrast, MCP-1 is able to induce PGE2 and PGF2alpha in a concentration-dependent manner but it does not appear to contribute to the increase in PG accumulation following IL-1beta stimulation. hCG inhibits IL-1beta-induced PG level. However, hCG has no effect on either basal or IL-1beta-mediated MCP-1 level.


CONCLUSIONS
PG are not involved in the regulation of MCP-1 production in endometrial cells. hCG appears to play a local function in the endometrium.
Unité de Recherche en Ontogénie et Reproduction et Centre de Recherche en Rhumatologie et Immunologie, Centre de Recherche du CHUL, 2705 Boul. Laurier, Ste-Foy, Québec, G1V 4G2, Canada.
Jihong
J
Kang
Ali
A
Akoum
Pierre
P
Chapdelaine
Philippe
P
Laberge
Patrice E
PE
Poubelle
Michel A
MA
Fortier
D000328:Adult; D002478:Cells, Cultured; D018932:Chemokine CCL2 / Q000187:drug effects / Q000378:metabolism*; D006063:Chorionic Gonadotropin / Q000378:metabolism / Q000494:pharmacology*; D003470:Culture Media; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D004717:Endometrium / Q000166:cytology* / Q000187:drug effects / Q000502:physiology; D005260:Female; D006801:Humans; D007375:Interleukin-1 / Q000378:metabolism / Q000494:pharmacology*; D008565:Membrane Proteins; D008875:Middle Aged; D011451:Prostaglandin-Endoperoxide Synthases / Q000187:drug effects / Q000378:metabolism; D011453:Prostaglandins / Q000378:metabolism*; D017154:Stromal Cells / Q000187:drug effects / Q000378:metabolism; D013997:Time Factors
C111835:CCL2 protein, human; D018932:Chemokine CCL2; D006063:Chorionic Gonadotropin; D003470:Culture Media; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007375:Interleukin-1; D008565:Membrane Proteins; D011453:Prostaglandins; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; C496511:PTGS1 protein, human; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases